Chronische koronare Herzkrankheit

Harald Gabriel1, Senta Graf1, Thomas Neunteufl1
1Klinische Abteilung für Kardiologie, Univ.-Klinik für Innere Medizin II, Medizinische Universität Wien, Wien, Austria

Tóm tắt

Từ khóa


Tài liệu tham khảo

Rose G, Hamilton PS, Keen H, Reid DD, McCartney P, Jarrett RJ (1977) Myocardial ischaemia, risk factors and death from coronary heart-disease. Lancet 1: 105–109

Nicholson A, White IR, Macfarlane P, Brunner E, Marmot M (1999) Rose questionnaire angina in younger men and women: gender differences in the relationship to cardiovascular risk factors and other reported symptoms. J Clin Epidemiol 52: 337–346

Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J (1998) Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21: 69–75

Kannel WB, Feinleib M (1972) Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol 29: 154–163

Murabito JM, Evans JC, Larson MG, Levy D (1993) Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation 88: 2548–2555

Campeau L (1976) Letter: Grading of angina pectoris. Circulation 54: 522–523

Gibson RS (1991) The diagnostic and prognostic value of exercise electrocardiography in asymptomatic subjects and stable symptomatic patients. Curr Opin Cardiol 6: 536–546

Marwick TH (1998) Current status of stress echocardiography for diagnosis and prognostic assessment of coronary artery disease. Coron Artery Dis 9: 411–426

Allman KC, Thomson LEJ (2001) Prognostic value of myocardial perfusion imaging in patients with known or suspected coronary artery disease. Eur Heart J 3: F5–F7

Machecourt J, Vanzetto G (2001) Myocardial perfusion imaging for the detection of coronary artery disease in patients with known or suspected disease. Eur Heart J 3: F2–F4

Czernin J, Schelbert HR (1994) Non-invasive quantification of myocardial blood flow and flow reserve using dynamic positron emission tomography. Wien Klin Wochenschr 106: 478–486

Raff GL, Gallagher MJ, O'Neill WW, Goldstein JA (2005) Diagnostic accuracy of non-invasive coronary angiography using 64-slice spiral computed tomography. J Am Coll Cardiol 46: 552–557

Leschka S, Alkadhi H, Plass A, Desbiolles L, Grunenfelder J, Marincek B, Wildermuth S (2005) Accuracy of MSCT coronary angiography with 64-slice technology: first experience. Eur Heart J 26: 1482–1487

Krakau I, Lapp H (2004) Das Herzkatheterbuch: Diagnostische und interventionelle Kathetertechniken. Thieme, Stuttgart New York

Pijls NH, Van Gelder B, Van der Voort P, et al (1995) Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation 92: 3183–3193

Pijls NH, De Bruyne B, Peels K, et al (1996) Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 334: 1703–1708

Fearon WF, Balsam LB, Farouque HM (2003) Novel index for invasively assessing the coronary microcirculation. Circulation 107: 3129–3132

Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG) (2006) Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 27: 1341–1381

De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601–1610

De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D (2003) European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 10 [Suppl 1]: S1–S78

Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, Held C, Nasman P, Wallen NH (1996) Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 17: 76–81

Dargie HJ, Ford I, Fox KM (1996) Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 17: 104–112

Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA (1999) Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281: 1927–1936

The IONA Study Group (2002) Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359: 1269–1275

Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 [Suppl 3]: 234S–264S

CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005) Clopidogrel vs. aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44: 720–732

Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253–259

Fox MK (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782–788

Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL (2004) Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109: 672–693

Bennett JS, Daugherty A, Herrington D, Greenland P, Roberts H, Taubert KA (2005) The use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association. Circulation 111: 1713–1716

Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 49–57

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288: 321–333

Khan NE, De Souza A, Mister R, et al (2004) A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. N Engl J Med 350: 21–28

Boden WE, O'Rourke RA, Teo KK, et al (2007) Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 356: 1503–1516